Carbiotix completes metformin study and provides EU funding update
Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the metformin study has now been completed after aligning with the project group. While the Polymerase Chain Reaction (PCR) results communicated on November 1st, 2023, indicated that 20% of patients in the intervention cohort responded positively to a prebiotic containing CarbiAXOS, experiencing an average improvement of 15% in HbA1c (blood glucose) levels and an upregulation of Short Chain Fatty Acid (SCFA) levels, the Next Generation Sequencing (NGS) results after bioinformatic analysis were inconclusive due to the study’s